American Epilepsy Society (AES): Written Comments to Norman E. "Ned" Sharpless, MD, Acting Commissioner of Food and Drugs, US Food and Drug Administration (FDA), Department of Health and Human Services (HHS) on Docket ID# FDA-2019-N-1482, Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments: Submitted on: July 16, 2019

• Type of Material: Article
• Authors: Timothy E. Welty, Drake University; Kevin E. Chapman, University of Colorado; Raymond Faught Jr, Emory University; Robert J. Kotloski, University of Wisconsin
• Language: English
• Date: 2019-10-22
• Publisher: SAGE Publications Inc.
• Publication Version: Final Published Version
• Copyright Statement: © The Author(s) 2019.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1177/1535759719878716
• Title of Journal or Parent Work: Epilepsy Currents
• Volume: 19
• Issue: 6
• Start Page: 361
• End Page: 368
• Grant/Funding Information: The author(s) received no financial support for the research, authorship, and/or publication of this article.
• Keywords: Hemp; Science & Technology; Neurosciences & Neurology; Clinical Neurology; Life Sciences & Biomedicine; Accuracy
• Research Categories: Health Sciences, Public Health; Health Sciences, Rehabilitation and Therapy; Biology, Neuroscience

Abstract

On April 3, 2019, the US Food and Drug Administration (FDA) announced a public hearing on May 31, 2019 and a call for written comments on the topic of cannabis and cannabis-derived compounds.1 Kevin Chapman, MD, spoke on behalf of the American Epilepsy Society (AES) at the public hearing. Transcripts of comments, including those by Dr Chapman, are available through the FDA website.